What is Zacks Research’s Estimate for EW Q1 Earnings?

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Zacks Research increased their Q1 2025 earnings estimates for Edwards Lifesciences in a research report issued to clients and investors on Tuesday, March 4th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $0.58 per share for the quarter, up from their previous forecast of $0.57. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences’ FY2025 earnings at $2.41 EPS, Q2 2026 earnings at $0.70 EPS and Q4 2026 earnings at $0.70 EPS.

A number of other research firms have also commented on EW. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. The Goldman Sachs Group lifted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Truist Financial reiterated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Evercore ISI dropped their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Price Performance

NYSE EW opened at $72.89 on Thursday. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12. The stock has a market capitalization of $42.99 billion, a P/E ratio of 10.46, a P/E/G ratio of 4.82 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The business’s fifty day moving average is $72.45 and its two-hundred day moving average is $70.35.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,739 shares of company stock valued at $2,799,104 over the last quarter. Corporate insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Van ECK Associates Corp boosted its position in shares of Edwards Lifesciences by 7.7% during the third quarter. Van ECK Associates Corp now owns 126,764 shares of the medical research company’s stock worth $8,951,000 after buying an additional 9,011 shares during the period. Forum Financial Management LP acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $203,000. Asset Management One Co. Ltd. boosted its holdings in Edwards Lifesciences by 0.9% during the third quarter. Asset Management One Co. Ltd. now owns 239,392 shares of the medical research company’s stock worth $15,797,000 after purchasing an additional 2,188 shares during the last quarter. QRG Capital Management Inc. lifted its position in Edwards Lifesciences by 66.6% during the 3rd quarter. QRG Capital Management Inc. now owns 77,245 shares of the medical research company’s stock worth $5,097,000 after buying an additional 30,892 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its stake in shares of Edwards Lifesciences by 66.2% during the 3rd quarter. Impax Asset Management Group plc now owns 12,964 shares of the medical research company’s stock worth $855,000 after buying an additional 5,164 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.